Showing results (231-240 of 258) with videos related to
Sort By:
Pageof 26
The Journal of Clinical and Aesthetic Dermatology|February 6, 2026
PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in DermatologyCourtney A Chau, Hilary E Baldwin, James Q Del Rosso, et al.Journal of the American Academy of Dermatology|January 22, 2024
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trialAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.Pediatric Dermatology|February 15, 2013
Therapeutic patient education in atopic dermatitis: worldwide experiencesJean-Francois Stalder, Claire Bernier, Alan Ball, et al.JAMA Dermatology|August 4, 2021
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical TrialAndrew Blauvelt, Henrique D Teixeira, Eric L Simpson, et al.Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|January 6, 2015
Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infantsThomas Luger, Mark Boguniewicz, Warner Carr, et al.Clinical and Experimental Dermatology|November 9, 2025
Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitisJonathan I Silverberg, Andreas Wollenberg, Linda Stein Gold, et al.The Journal of Allergy and Clinical Immunology. in Practice|February 15, 2024
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 PopulationJonathan Corren, Stanley J Szefler, Ellen Sher, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|July 11, 2024
Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitisJonathan I Silverberg, Melinda Gooderham, Norito Katoh, et al.JAMA Dermatology|September 18, 2024
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical TrialsEric L Simpson, Lawrence F Eichenfield, Javier Alonso-Llamazares, et al.Dermatitis : Contact, Atopic, Occupational, Drug|January 10, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension TrialEric L Simpson, Lawrence F Eichenfield, Kim A Papp, et al.Pageof 26